查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1965779

婴儿癫痫治疗市场－全球产业规模、份额、趋势、机会、预测：依治疗层级、药物类型、剂量、地区和竞争格局划分，2021-2031年

Infantile Spasms Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Therapeutic Class, By Drug Type, By Dosage, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

全球婴儿癫痫治疗市场预计将从 2025 年的 1.4711 亿美元成长到 2031 年的 1.8819 亿美元，复合年增长率为 4.19%。

该领域的治疗方法主要涉及特定药物疗法，例如促肾上腺皮质激素 (ACTH) 和Vigabatrin，这些药物对于控制癫痫发作和缓解婴儿的超节律至关重要。由于临床上迫切需要快速治疗以防止神经发育障碍，以及先进的基因筛检提高了早期诊断率，该市场正在不断增长。根据美国癫痫协会 2024 年的数据，这种严重的疾病影响着约 2000 分之一的儿童，凸显了全球对专门药物疗法的持续需求。

市场概览
预测期 2027-2031
市场规模：2025年 1.4711亿美元
市场规模：2031年 1.8819亿美元
复合年增长率：2026-2031年 4.19%
成长最快的细分市场 Vigabatrin
最大的市场 北美洲

然而，获得已通过核准的孤儿药成本高昂，且监管机构对安全性的严格监控，都对市场成长构成了重大障碍。第一线治疗药物可能出现的严重毒性反应，需要严格的风险管理通讯协定，例如监测视野缩小，这给医疗服务提供者带来了巨大的后勤挑战。这些日益增长的财务和行政需求，使得药物分发流程更加复杂，限制了病患获得必要治疗的机会，尤其是在缺乏改善医保报销机制的地区。

市场驱动因素

该市场的特点是拥有强大的临床研发管线，并且针对处于研发阶段的癫痫性脑病变和发育性癫痫性脑病变的策略性投资不断增加。製药公司已采取优先研发用于治疗婴儿癫痫症候群的后期药物的策略，产业整合正在显着推进。例如，2024年10月，H. Lundbeck宣布达成最终协议，将以约26亿美元的以金额为准收购Longboard Pharmaceuticals，旨在确保取得用于治疗罕见癫痫（例如West症候群）的药物bexicaserin。这种商业性发展势头得益于非营利组织持续的基础研究资助。 CURE Epilepsy在2024年津贴220万美元，用于加速科学突破，凸显了该产业正在发生重大转变，即透过积极的研发来拓展治疗选择。

同时，由于有利的监管激励措施和针对关键给药难题而开发的新型製剂，该领域正在取得进展。监管机构正积极推动罕见儿童疾病治疗药物的商业化，透过「孤儿药认定」赋予生产者显着的市场独占权和优先待遇。这些激励措施促进了以患者为中心的产品的开发，简化了看护者的用药流程。例如，在2024年6月的新闻稿中，Pyrus Pharmaceuticals宣布美国FDA已核准Vigafide上市，这是一种根据孤儿药认定计画开发的婴儿癫痫治疗药物。这是首个可取代复杂粉末的即用型口服液製剂。这项进展表明，法规结构正在直接支持优化治疗方法的引入，从而提高患者的用药依从性。

市场挑战

获得孤儿药物已通过核准的高昂成本，加上严格的监管安全监测，对市场扩张构成了重大障碍。这些财务和行政负担直接阻碍了市场成长，限制了患者获得必要治疗的机会。一线疗法的高昂价格给医疗预算和保险公司带来了沉重负担，常常导致保险拒付和核准延迟。此外，对于具有严重毒性的药物，必须进行严格的风险评估，这造成了巨大的后勤障碍，要求医疗机构投入大量资源用于安全监测项目，使药物分发更加复杂，并限制了能够开具这些特殊药物的医疗机构数量。

保险保障不足进一步加剧了这种困境，将经济负担转嫁到家庭身上。根据美国国家罕见疾病组织 (NORD) 2024 年的报告，美国有 22 个州因处方药自付费用保障政策极度匮乏而被评为 C 级，另有 3 个州因完全没有保障而被评为 F 级。这种缺乏全面经济保障的情况意味着，即使有有效的治疗方法，经济负担也会阻碍患者开始治疗，从而有效地缩小了商业性可行性的患者群体。

市场趋势

精准医疗和基因谱分析的应用正在从根本上重塑治疗格局，将治疗模式从频谱类固醇转向病因特异性干预。随着我们对婴儿癫痫症候群遗传结构的理解不断加深，临床医生越来越重视基因组检测，以便在启动标准治疗之前识别可治疗的代谢或遗传病因。这一趋势正在推动标靶治疗的发展，这些疗法作用于特定的生物通路，而不仅仅是抑制症状。根据发表在2024年2月《基因》（Genes，巴塞尔）杂誌上题为「婴儿癫痫症候群的遗传进展和精准医疗的潜力」的论文，研究人员目前已发现70多个与此综合征相关的单基因致病变异，这一发现正在加速对mTOR抑製剂等标靶药物的临床需求。

同时，数位癫痫监测与人工智慧的融合正在变革诊断通讯协定和疗效追踪，直接应对识别细微癫痫发作的挑战。新型机器学习驱动的诊断工具正在开发中，用于分析家庭影片数据，从而实现快速远端评估和早期治疗，这对于维持神经发育功能至关重要。这项技术进步透过减少长期住院期间对视讯脑电图监测的依赖并最大限度地减少诊断延误，扩大了商业性可行性的患者群体。根据2025年1月发布的CURE Epilepsy报告（基于2024年美国癫痫协会年会上公布的研究结果），一种新开发的AI模型透过分析看护者录製的影片，在检测婴儿癫痫发作方面展现出85%的准确率。这凸显了数位医疗在简化患者识别和管理方面的潜力。

目录

第一章概述

第二章：调查方法

第三章执行摘要

第四章：客户心声

第五章：婴儿癫痫治疗药物的全球市场展望

  • 市场规模及预测
    • 按金额
  • 市占率及预测
    • 治疗分类（抗癫痫药、皮质类固醇、其他）
    • 依药物类型（Vigabatrin、促肾上腺皮质激素、其他）
    • 剂型（固态、液体）
    • 按地区
    • 按公司（2025 年）
  • 市场地图

第六章：北美婴儿癫痫治疗药物市场展望

  • 市场规模及预测
  • 市占率及预测
  • 北美洲：国别分析
    • 我们
    • 加拿大
    • 墨西哥

第七章：欧洲婴儿癫痫治疗药物市场展望

  • 市场规模及预测
  • 市占率及预测
  • 欧洲：国别分析
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙

第八章：亚太地区婴儿癫痫治疗药物市场展望

  • 市场规模及预测
  • 市占率及预测
  • 亚太地区：国别分析
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳洲

第九章：中东和非洲婴儿癫痫治疗药物市场展望

  • 市场规模及预测
  • 市占率及预测
  • 中东与非洲：国别分析
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非

第十章：南美婴儿癫痫治疗药物市场展望

  • 市场规模及预测
  • 市占率及预测
  • 南美洲：国别分析
    • 巴西
    • 哥伦比亚
    • 阿根廷

第十一章 市场动态

  • 促进因素
  • 任务

第十二章 市场趋势与发展

  • 併购
  • 产品发布
  • 近期趋势

第十三章：全球婴幼儿癫痫治疗市场：SWOT分析

第十四章：波特五力分析

  • 产业竞争
  • 新进入者的潜力
  • 供应商的议价能力
  • 顾客权力
  • 替代品的威胁

第十五章 竞争格局

  • Merck KGaA
  • Novartis AG
  • Sanofi SA
  • Pfizer Inc
  • Johnson & Johnson
  • Abbott Laboratories Inc
  • Teva Pharmaceutical Industries Ltd
  • Bausch Health Companies Inc.
  • AstraZeneca PLC
  • GSK PLC

第十六章 策略建议

第十七章：关于研究公司及免责声明

简介目录
Product Code: 18993

The Global Infantile Spasms Therapeutics Market is projected to expand from USD 147.11 Million in 2025 to USD 188.19 Million by 2031, reflecting a compound annual growth rate of 4.19%. Therapeutics in this sector primarily involve specific pharmaceutical interventions, such as adrenocorticotropic hormone and vigabatrin, which are essential for arresting epileptic spasms and resolving hypsarrhythmia in infants. The market is driven by the urgent clinical need for rapid treatment to prevent neurodevelopmental regression, along with rising early diagnosis rates enabled by advanced genetic screening. Data from the Epilepsy Alliance America in 2024 indicates that this severe disorder affects approximately one in every 2,000 children, underscoring a consistent global demand for specialized pharmacological management.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 147.11 Million
Market Size 2031USD 188.19 Million
CAGR 2026-20314.19%
Fastest Growing SegmentVigabatrin
Largest MarketNorth America

However, market growth faces significant hurdles due to the high acquisition costs of approved orphan drugs and the rigorous safety monitoring enforced by regulatory agencies. The severe toxicity associated with primary treatments necessitates strict risk management protocols, such as monitoring for visual field constriction, which imposes substantial logistical challenges on healthcare providers. These elevated financial and administrative demands complicate the distribution process and restrict patient access to necessary therapies, particularly in regions that lack comprehensive reimbursement frameworks.

Market Driver

The market is defined by a robust clinical pipeline and increasing strategic investments focused on developmental and epileptic encephalopathies. Pharmaceutical companies are prioritizing late-stage assets for Infantile Epileptic Spasms Syndrome, resulting in significant industry consolidation. For example, H. Lundbeck A/S announced a definitive agreement in October 2024 to acquire Longboard Pharmaceuticals for an equity value of roughly $2.6 billion, aiming to secure access to bexicaserin for rare epilepsies like West syndrome. This commercial momentum is supported by continued non-profit funding for foundational research; CURE Epilepsy awarded $2.2 million in grants in 2024 to accelerate scientific breakthroughs, highlighting a decisive industry shift toward expanding therapeutic options through aggressive research and development.

Concurrently, the sector is advancing due to favorable regulatory incentives and the creation of novel formulations that solve critical administration issues. Regulatory bodies actively promote the commercialization of treatments for rare pediatric diseases via Orphan Drug Designations, offering manufacturers crucial market exclusivity and benefits. These incentives have fostered the development of patient-centric products that simplify dosing for caregivers. For instance, Pyros Pharmaceuticals announced in a June 2024 press release that the U.S. FDA approved Vigafyde, the first ready-to-use oral solution for infantile spasms developed under the Orphan Drug pathway to replace complex powder formulations. Such progress illustrates how regulatory frameworks directly support the launch of optimized therapies that improve patient compliance.

Market Challenge

The prohibitive acquisition costs of approved orphan drugs, combined with stringent regulatory safety monitoring, constitute a formidable barrier to market expansion. These financial and administrative burdens directly hamper growth by restricting patient access to essential therapies. The high price of first-line treatments places immense strain on healthcare budgets and insurance providers, often leading to coverage denials or delayed approvals. Furthermore, the rigorous risk evaluation mandated for drugs with severe toxicity profiles creates significant logistical hurdles, requiring healthcare providers to dedicate substantial resources to safety monitoring programs, which complicates distribution and limits the number of centers capable of prescribing these specialized medications.

This challenging environment is further exacerbated by inadequate insurance protections that transfer economic liability to families. According to the National Organization for Rare Disorders in 2024, twenty-two U.S. states received a C grade for maintaining only minimal out-of-pocket prescription drug cost protection policies, while three states received an F grade for having absolutely no such protections in place. This lack of comprehensive financial safeguards means that even when effective therapeutics are available, the economic burden can prevent therapy initiation, effectively reducing the commercially addressable patient population.

Market Trends

The adoption of precision medicine and genetic profiling is fundamentally reshaping the therapeutic landscape by shifting treatment paradigms from broad-spectrum corticosteroids to etiology-specific interventions. As the understanding of the genetic architecture of Infantile Epileptic Spasms Syndrome deepens, clinicians are increasingly prioritizing genetic panels to identify treatable metabolic or genetic causes before initiating standard therapies. This trend is driving the development of targeted therapeutics that address specific biological pathways rather than merely suppressing symptoms. According to an article in Genes (Basel) from February 2024, titled 'Genetic Advancements in Infantile Epileptic Spasms Syndrome and Opportunities for Precision Medicine,' researchers have now identified over 70 single gene pathogenic variants associated with the syndrome, a discovery that is accelerating the clinical demand for targeted agents such as mTOR inhibitors.

Simultaneously, the integration of digital seizure monitoring and artificial intelligence is transforming diagnostic protocols and efficacy tracking, directly addressing the challenge of identifying subtle spasms. Novel diagnostic tools leveraging machine learning are being developed to analyze home video data, allowing for rapid remote assessment and earlier therapy initiation, which is critical for preserving neurodevelopmental function. This technological evolution reduces the dependency on prolonged inpatient video-EEG monitoring and expands the commercially addressable patient population by minimizing diagnostic delays. According to a January 2025 CURE Epilepsy report on findings presented at the 2024 American Epilepsy Society Annual Meeting, a newly developed AI model for analyzing caregiver-recorded videos demonstrated an accuracy of 85% in detecting infantile spasms, highlighting the potential of digital health to streamline patient identification and management.

Key Market Players

  • Merck KGaA
  • Novartis AG
  • Sanofi SA
  • Pfizer Inc
  • Johnson & Johnson
  • Abbott Laboratories Inc
  • Teva Pharmaceutical Industries Ltd
  • Bausch Health Companies Inc.
  • AstraZeneca PLC
  • GSK PLC

Report Scope

In this report, the Global Infantile Spasms Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Infantile Spasms Therapeutics Market, By Therapeutic Class

  • Anticonvulsants
  • Corticosteroids
  • Others

Infantile Spasms Therapeutics Market, By Drug Type

  • Vigabatrin
  • Adrenocorticotropic Hormone
  • Others

Infantile Spasms Therapeutics Market, By Dosage

  • Solid
  • Liquid

Infantile Spasms Therapeutics Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Infantile Spasms Therapeutics Market.

Available Customizations:

Global Infantile Spasms Therapeutics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Infantile Spasms Therapeutics Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Therapeutic Class (Anticonvulsants, Corticosteroids, Others)
    • 5.2.2. By Drug Type (Vigabatrin, Adrenocorticotropic Hormone, Others)
    • 5.2.3. By Dosage (Solid, Liquid)
    • 5.2.4. By Region
    • 5.2.5. By Company (2025)
  • 5.3. Market Map

6. North America Infantile Spasms Therapeutics Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Therapeutic Class
    • 6.2.2. By Drug Type
    • 6.2.3. By Dosage
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Infantile Spasms Therapeutics Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Therapeutic Class
        • 6.3.1.2.2. By Drug Type
        • 6.3.1.2.3. By Dosage
    • 6.3.2. Canada Infantile Spasms Therapeutics Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Therapeutic Class
        • 6.3.2.2.2. By Drug Type
        • 6.3.2.2.3. By Dosage
    • 6.3.3. Mexico Infantile Spasms Therapeutics Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Therapeutic Class
        • 6.3.3.2.2. By Drug Type
        • 6.3.3.2.3. By Dosage

7. Europe Infantile Spasms Therapeutics Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Therapeutic Class
    • 7.2.2. By Drug Type
    • 7.2.3. By Dosage
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Infantile Spasms Therapeutics Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Therapeutic Class
        • 7.3.1.2.2. By Drug Type
        • 7.3.1.2.3. By Dosage
    • 7.3.2. France Infantile Spasms Therapeutics Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Therapeutic Class
        • 7.3.2.2.2. By Drug Type
        • 7.3.2.2.3. By Dosage
    • 7.3.3. United Kingdom Infantile Spasms Therapeutics Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Therapeutic Class
        • 7.3.3.2.2. By Drug Type
        • 7.3.3.2.3. By Dosage
    • 7.3.4. Italy Infantile Spasms Therapeutics Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Therapeutic Class
        • 7.3.4.2.2. By Drug Type
        • 7.3.4.2.3. By Dosage
    • 7.3.5. Spain Infantile Spasms Therapeutics Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Therapeutic Class
        • 7.3.5.2.2. By Drug Type
        • 7.3.5.2.3. By Dosage

8. Asia Pacific Infantile Spasms Therapeutics Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Therapeutic Class
    • 8.2.2. By Drug Type
    • 8.2.3. By Dosage
    • 8.2.4. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Infantile Spasms Therapeutics Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Therapeutic Class
        • 8.3.1.2.2. By Drug Type
        • 8.3.1.2.3. By Dosage
    • 8.3.2. India Infantile Spasms Therapeutics Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Therapeutic Class
        • 8.3.2.2.2. By Drug Type
        • 8.3.2.2.3. By Dosage
    • 8.3.3. Japan Infantile Spasms Therapeutics Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Therapeutic Class
        • 8.3.3.2.2. By Drug Type
        • 8.3.3.2.3. By Dosage
    • 8.3.4. South Korea Infantile Spasms Therapeutics Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Therapeutic Class
        • 8.3.4.2.2. By Drug Type
        • 8.3.4.2.3. By Dosage
    • 8.3.5. Australia Infantile Spasms Therapeutics Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Therapeutic Class
        • 8.3.5.2.2. By Drug Type
        • 8.3.5.2.3. By Dosage

9. Middle East & Africa Infantile Spasms Therapeutics Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Therapeutic Class
    • 9.2.2. By Drug Type
    • 9.2.3. By Dosage
    • 9.2.4. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Infantile Spasms Therapeutics Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Therapeutic Class
        • 9.3.1.2.2. By Drug Type
        • 9.3.1.2.3. By Dosage
    • 9.3.2. UAE Infantile Spasms Therapeutics Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Therapeutic Class
        • 9.3.2.2.2. By Drug Type
        • 9.3.2.2.3. By Dosage
    • 9.3.3. South Africa Infantile Spasms Therapeutics Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Therapeutic Class
        • 9.3.3.2.2. By Drug Type
        • 9.3.3.2.3. By Dosage

10. South America Infantile Spasms Therapeutics Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Therapeutic Class
    • 10.2.2. By Drug Type
    • 10.2.3. By Dosage
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Infantile Spasms Therapeutics Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Therapeutic Class
        • 10.3.1.2.2. By Drug Type
        • 10.3.1.2.3. By Dosage
    • 10.3.2. Colombia Infantile Spasms Therapeutics Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Therapeutic Class
        • 10.3.2.2.2. By Drug Type
        • 10.3.2.2.3. By Dosage
    • 10.3.3. Argentina Infantile Spasms Therapeutics Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Therapeutic Class
        • 10.3.3.2.2. By Drug Type
        • 10.3.3.2.3. By Dosage

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Infantile Spasms Therapeutics Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Merck KGaA
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Novartis AG
  • 15.3. Sanofi SA
  • 15.4. Pfizer Inc
  • 15.5. Johnson & Johnson
  • 15.6. Abbott Laboratories Inc
  • 15.7. Teva Pharmaceutical Industries Ltd
  • 15.8. Bausch Health Companies Inc.
  • 15.9. AstraZeneca PLC
  • 15.10. GSK PLC

16. Strategic Recommendations

17. About Us & Disclaimer